Continuing Education Opportunities

ClotCare Online Resource does not offer continuing education credit. We do, however, provide information and links to continuing education opportunities that we feel may be of value to our users. We hope you find this list useful. If you know of a continuing education opportunity that you feel may be useful to other ClotCare users, please tell us about it. You may contact us at webmaster@clotcare.org. If you are specifically interested in anticoagulation training programs, check out our Training Programs page.

The University of Illinois at Chicago Office of Continuing Education and Meeting Services-Programs offers a number of continuing education opportunities relating to anticoagulation and antithrombotic therapy. To review current opportunities, go to http://www.pharmacyce.uic.edu/Public/Catalog/

Thrombosis-Consult.com has a Free CME section that lists a number of Thrombosis-related CME opportunities. These listings are located at http://thrombosis.freecme.com/gallcourses.php

ThrombosisClinic.com is a continuing medical education resource for health care professionals emphasizing the latest in emerging approaches in the diagnosis, treatment, and prevention of thrombosis. Visit http://www.ThrombosisClinic.com for more information.

HemostasisCME.org offers a number of continuing education opportunities relating to thrombosis. Visit http://www.hemostasiscme.org/
ActivitiesByTopic.asp?tpc=3&title=Coagulopathy for a list of current programs.

The ASHP has thrombosis-related CE programs and webinars online at www.improvingpatientoutcomes.com.

The heart.org has CE programs online at:
Thrombosis: theheart.org/condition/thrombosis-risk/section/cme-programs.do
Atrial Fibrillation: theheart.org/condition/arrhythmia-ep/section/cme-programs.do

Effectively Managing Oral Anticoagulation: 4 part series presented by Discovery Health featuring Jack E. Ansell, MD, B. Gail Macik, MD and Alan K. Jacobson, MD. discoveryhealthcme.discovery.com/beyond/miniPlayer.html?playerId=1225901422

Additional CE Opportunities

• UC Davis Update on the Management of Thromboembolic Disorders, Oct. 11-13, 2010

Programs no Longer Offering Credit

• Real World Best Practices for DVT Prophylaxis
• Challenges in Dosing Low Molecular Weight Heparin
• Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion

UC Davis Update on the Management of Thromboembolic Disorders

October 11-13, 2010

The Meritage Hotel and Spa
Napa, California
Online Hotel reservations: https://gc.synxis.com/rez.aspx?hotel=27258&
adult=1&step=1&shell=APCMH&chain=10237&
template=APCMH&avcurrency=USD&group=GRPUCDMTD

The nationally respected faculty presenting and interacting with participants at this activity include a principal author of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for Prevention of Venous Thromboembolism (VTE), a member of the National Quality Forum steering committee for VTE initiatives, a nationally recognized leader in anticoagulation programs for pharmacists, an editorial board member for the American Thoracic Society's CHEST Journal, and an authority on cancer-related thrombosis and the role of the hemostatic system in sickle cell disease pathogenesis. Collectively, they have written hundreds of articles on anticoagulation management.

Sponsored by UC Davis Health System

For online conference registration: https://chtapps.ucdmc.ucdavis.edu/
servlet/CmeSignIn?ccode=DVTUP11

To print the brochure: http://www.ucdmc.ucdavis.edu/cme/
conferences/pdfs/DVTUP11-10-11-10e.pdf

Real World Best Practices for DVT Prophylaxis

CME Credit hours: 1.5 AMA PRA Category 1 credits

Release date: July 25, 2006
Available for credit through: July 25, 2007

Program Description

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. While unfractionated heparin (UFH) has been the standard treatment of VTE for many years, low-molecular-weight-heparins (LMWHs) are now commonly used as a therapeutic alternative. Effective prophylaxis and intervention are essential in minimizing VTE risk and reducing the incidence of life-threatening events. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.

Target Audience

This activity is intended for healthcare providers who treat DVT.

Educational Objectives

Upon completion of this educational activity participants will be able to:

• Discuss the management of patients with venous thromboembolism: Challenges and Opportunities
• Understand treatment and secondary prophylaxis in VTE
• Discuss treatment options for management of acute PE
• Understand the current issues and controversies in VTE treatment and prophylaxis
• Discuss the new and current treatment options for DVT by examining current data
• Identify special considerations for the medically ill or patients with comorbidities

Faculty

• Paul E. Marik, MD, FCCP, FCCM
• Arthur P. Wheeler, MD, FCCP
• Jamie E. Siegel, MD
• Sandra L. Kane-Gill, PharmD, MSc.

View Program

The program is available online at:
http://www.cmediscovery.com/dvt/index.html

Challenges in Dosing Low Molecular Weight Heparin

CME Credit hours: 1.0

Release date: November 15, 2005
Available for credit through: November 15, 2007

Program Description

Anticoagulants are used in a wide variety of patients, for both therapeutic purposes and as prophylaxis against thromboembolism. The efficacy of these agents has been well established in clinical trials.

Unfractionated heparin can be hard to use, it binds to plasma proteins, and so there is wide variation in its anticoagulant effect. Vigilant monitoring of the PTT is necessary. Heparin-induced thrombocytopenia occurs about 3% of the time and this can be a big problem when it occurs.

Low molecular weight heparins are produced by depolymerization of unfractionated heparin, rendering them smaller and thus more bioavailable. There is less binding to plasma proteins and less inactivation by platelet factor 4. Because of their more predicable effects, routine laboratory monitoring for dose adjustment is usually not required.

There are solid clinical trial data indicating that low molecular weight heparins can be used as an alternative to unfractionated heparins. This program’s intention is NOT to review those data. Instead, this program features a discussion between four experts in critical care medicine. The discussion addresses the challenges in dosing and monitoring patients at the extremes of body weight, patients with renal insufficiency, and critically ill patients with altered plasma volume.

Target Audience

This activity is intended for Cardiologists, Hematologists, Intensivists, Pharmacists and other healthcare professionals who treat patients with LMWH.

Educational Objectives

Upon completion of this activity, participants will be able to:

• Maximize safety and efficacy while reducing harm when dosing LMWH.
• Identify dosing considerations in special populations (i.e. critically ill, obese, renal impaired).
• Have a greater understanding of the pharmaco-economics surrounding LMWH.

Faculty

• Joseph F. Dasta, MSc., FCCM, FCCP
• Steven M. Hollenberg, MD
• Sandra L. Kane-Gill, PharmD., MSc.
• Arthur P. Wheeler, MD

View Program

The program is available online at:
http://www.arcmesa.org/lmwh/default.aspx

Cancer and Thromboembolism

Pharmion Corporation has provided ClotCare Online Resource with a publication written by Joseph A. Caprini, MD, MS, FACS, RVT. This case presentation and discussion is entitled Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion. If you are interested in receiving CME credit for reviewing this publication, simply complete the questions provided and follow the instructions that accompany them.

You will need Adobe Reader to view this document. You may download a free copy from Adobe's website at http://www.adobe.com/products/acrobat/readstep2.html.

Read Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion